1244 related articles for article (PubMed ID: 27991835)
1. Parent-Reported Improvements in Family Functioning in a Randomized Controlled Trial of Lisdexamfetamine for Treatment of Parental Attention-Deficit/Hyperactivity Disorder.
Babinski DE; Waxmonsky JG; Waschbusch DA; Humphery H; Pelham WE
J Child Adolesc Psychopharmacol; 2017 Apr; 27(3):250-257. PubMed ID: 27991835
[TBL] [Abstract][Full Text] [Related]
2. Does pharmacological treatment of ADHD in adults enhance parenting performance? Results of a double-blind randomized trial.
Waxmonsky JG; Waschbusch DA; Babinski DE; Humphrey HH; Alfonso A; Crum KI; Bernstein M; Slavec J; Augustus JN; Pelham WE
CNS Drugs; 2014 Jul; 28(7):665-77. PubMed ID: 24796970
[TBL] [Abstract][Full Text] [Related]
3. Acute Effects of Parent Stimulant Medication Versus Behavioral Parent Training on Mothers' ADHD, Parenting Behavior, and At-Risk Children.
Chronis-Tuscano A; French W; Strickland J; Sasser T; Gonzalez ENS; Whitlock KB; Stein MA
J Clin Psychiatry; 2020 Sep; 81(5):. PubMed ID: 32926603
[TBL] [Abstract][Full Text] [Related]
4. A pilot study of stimulant medication for adults with attention-deficit/hyperactivity disorder (ADHD) who are parents of adolescents with ADHD: the acute effects of stimulant medication on observed parent-adolescent interactions.
Babinski DE; Waxmonsky JG; Waschbusch DA; Humphrey H; Alfonso A; Crum KI; Bernstein M; Slavec J; Augustus JN; Pelham WE
J Child Adolesc Psychopharmacol; 2014 Dec; 24(10):582-5. PubMed ID: 25386742
[TBL] [Abstract][Full Text] [Related]
5. Parent-reported executive function behaviors and clinician ratings of attention-deficit/hyperactivity disorder symptoms in children treated with lisdexamfetamine dimesylate.
Findling RL; Adeyi B; Dirks B; Babcock T; Scheckner B; Lasser R; DeLeon A; Ginsberg LD
J Child Adolesc Psychopharmacol; 2013 Feb; 23(1):28-35. PubMed ID: 23410139
[TBL] [Abstract][Full Text] [Related]
6. Lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study.
Adler LA; Dirks B; Deas PF; Raychaudhuri A; Dauphin MR; Lasser RA; Weisler RH
J Clin Psychiatry; 2013 Jul; 74(7):694-702. PubMed ID: 23945447
[TBL] [Abstract][Full Text] [Related]
7. Treating parents with attention-deficit/hyperactivity disorder: the effects of behavioral parent training and acute stimulant medication treatment on parent-child interactions.
Babinski DE; Waxmonsky JG; Pelham WE
J Abnorm Child Psychol; 2014 Oct; 42(7):1129-40. PubMed ID: 24687848
[TBL] [Abstract][Full Text] [Related]
8. The Effectiveness and Tolerability of Central Nervous System Stimulants in School-Age Children with Attention-Deficit/Hyperactivity Disorder and Disruptive Mood Dysregulation Disorder Across Home and School.
Baweja R; Belin PJ; Humphrey HH; Babocsai L; Pariseau ME; Waschbusch DA; Hoffman MT; Akinnusi OO; Haak JL; Pelham WE; Waxmonsky JG
J Child Adolesc Psychopharmacol; 2016 Mar; 26(2):154-63. PubMed ID: 26771437
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
Najib J
Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715
[TBL] [Abstract][Full Text] [Related]
10. Effects of maternal stimulant medication on observed parenting in mother-child dyads with attention-deficit/hyperactivity disorder.
Chronis-Tuscano A; Rooney M; Seymour KE; Lavin HJ; Pian J; Robb A; Efron L; Conlon C; Stein MA
J Clin Child Adolesc Psychol; 2010; 39(4):581-7. PubMed ID: 20589568
[TBL] [Abstract][Full Text] [Related]
11. Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate.
Nagy P; Häge A; Coghill DR; Caballero B; Adeyi B; Anderson CS; Sikirica V; Cardo E
Eur Child Adolesc Psychiatry; 2016 Feb; 25(2):141-9. PubMed ID: 25999292
[TBL] [Abstract][Full Text] [Related]
12. Health-related quality of life and functional outcomes from a randomized-withdrawal study of long-term lisdexamfetamine dimesylate treatment in children and adolescents with attention-deficit/hyperactivity disorder.
Banaschewski T; Johnson M; Lecendreux M; Zuddas A; Adeyi B; Hodgkins P; Squires LA; Coghill DR
CNS Drugs; 2014 Dec; 28(12):1191-203. PubMed ID: 25139785
[TBL] [Abstract][Full Text] [Related]
13. Self-Reported quality of life in adults with attention-deficit/hyperactivity disorder and executive function impairment treated with lisdexamfetamine dimesylate: a randomized, double-blind, multicenter, placebo-controlled, parallel-group study.
Adler LA; Dirks B; Deas P; Raychaudhuri A; Dauphin M; Saylor K; Weisler R
BMC Psychiatry; 2013 Oct; 13():253. PubMed ID: 24106804
[TBL] [Abstract][Full Text] [Related]
14. Review of lisdexamfetamine dimesylate in children and adolescents with attention deficit/hyperactivity disorder.
Najib J; Didenko E; Meleshkina D; Yusupov K; Maw K; Ramnarain J; Tabassum M
Curr Med Res Opin; 2020 Oct; 36(10):1717-1735. PubMed ID: 32845786
[TBL] [Abstract][Full Text] [Related]
15. Treatment With Lisdexamfetamine Dimesylate Improves Self- and Informant-Rated Executive Function Behaviors and Clinician- and Informant-Rated ADHD Symptoms in Adults: Data From a Randomized, Double-Blind, Placebo-Controlled Study.
Weisler R; Ginsberg L; Dirks B; Deas P; Adeyi B; Adler LA
J Atten Disord; 2017 Dec; 21(14):1198-1207. PubMed ID: 24464328
[TBL] [Abstract][Full Text] [Related]
16. Health-related quality of life and functional outcomes from a randomized, controlled study of lisdexamfetamine dimesylate in children and adolescents with attention deficit hyperactivity disorder.
Banaschewski T; Soutullo C; Lecendreux M; Johnson M; Zuddas A; Hodgkins P; Adeyi B; Squires LA; Coghill D
CNS Drugs; 2013 Oct; 27(10):829-40. PubMed ID: 23893527
[TBL] [Abstract][Full Text] [Related]
17. Effect of lisdexamfetamine dimesylate on parent-rated measures in children aged 6 to 12 years with attention-deficit/hyperactivity disorder: a secondary analysis.
Lopez FA; Ginsberg LD; Arnold V
Postgrad Med; 2008 Sep; 120(3):89-102. PubMed ID: 18824828
[TBL] [Abstract][Full Text] [Related]
18. Impact of a behavioural sleep intervention on symptoms and sleep in children with attention deficit hyperactivity disorder, and parental mental health: randomised controlled trial.
Hiscock H; Sciberras E; Mensah F; Gerner B; Efron D; Khano S; Oberklaid F
BMJ; 2015 Jan; 350():h68. PubMed ID: 25646809
[TBL] [Abstract][Full Text] [Related]
19. Beyond symptom control for attention-deficit hyperactivity disorder (ADHD): what can parents do to improve outcomes?
Tarver J; Daley D; Sayal K
Child Care Health Dev; 2015 Jan; 41(1):1-14. PubMed ID: 24910021
[TBL] [Abstract][Full Text] [Related]
20. Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD.
Lachaine J; Sikirica V; Mathurin K
BMC Psychiatry; 2016 Jan; 16():11. PubMed ID: 26774811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
